ESR1 and breast carcinoma: Breast cancer-specific survival also favored ET recipients in both ER ≥ 10% (95.3% vs. 87.1%, p < 0.001, Fig. 2a) and ER 1–9% groups (93.9% vs. 89.7%, p = 0.005, Fig. 2b).